balance equationreview2023-09-30
Difference 1403000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.
Revenue
$243.68M
Fiscal year ended 2026-06-30Operating income
-$107.08M
Fiscal year ended 2026-06-30Free cash flow
-$71.54M
Fiscal year ended 2026-06-30BridgeBio Pharma, Inc. (BBIO) reported revenue of $243.68M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from BridgeBio Pharma, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $243.68M | $194.52M | $154.18M | $120.70M | $110.56M | $116.63M | $5.88M | $2.73M | $2.17M | $211.12M |
| Cost of revenue | $15.05M | $9.94M | $8.11M | $6.56M | $3.65M | $2.64M | $2.08M | $598.00K | $598.00K | $598.00K |
| Gross profit | $228.63M | $184.58M | $146.07M | $114.14M | $106.91M | $113.99M | $3.80M | $2.13M | $1.57M | $210.52M |
| Operating income | -$107.08M | -$105.96M | -$139.56M | -$145.20M | -$134.28M | -$104.37M | -$226.03M | -$191.75M | -$175.54M | $343.00K |
| Net income | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Research & development | $149.45M | $126.64M | $116.42M | $112.87M | $111.23M | $111.43M | $130.35M | $120.44M | $114.70M | $140.97M |
| Weighted-average diluted shares | shares 195.79M | shares 194.79M | Unavailable | shares 191.85M | shares 190.52M | shares 190.15M | Unavailable | shares 188.51M | shares 187.59M | shares 178.71M |
| Pretax income | -$155.89M | Unavailable | -$194.76M | -$186.48M | -$181.66M | Unavailable | -$266.24M | -$164.25M | -$75.54M | Unavailable |
| Income tax expense | $0 | Unavailable | -$120.00K | -$1.54M | $2.10M | $0 | $1.15M | $0 | $0 | $0 |
| Diluted EPS | $-0.78 | $-0.84 | Unavailable | $-0.95 | $-0.95 | $-0.88 | Unavailable | $-0.86 | $-0.39 | $-0.20 |
| Selling, general & administrative | $186.26M | $163.90M | $158.08M | $137.62M | $129.15M | $106.36M | $94.78M | $68.82M | $59.52M | $65.81M |
| General & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $677.91M | $879.89M | $570.12M | $642.95M | $748.95M | $540.60M | $681.10M | $266.32M | $407.96M | $475.22M |
| Total assets | $1.22B | $1.37B | $936.02M | $998.25M | $1.08B | $881.64M | $919.34M | $664.98M | $794.38M | $849.33M |
| Current assets | $1.09B | $1.24B | $797.75M | $839.38M | $912.28M | $695.17M | $720.69M | $444.58M | $616.24M | $783.42M |
| Total liabilities | $3.72B | $3.64B | $3.01B | $2.92B | $2.86B | $2.52B | $2.38B | $1.88B | $1.88B | $1.89B |
| Current liabilities | $890.65M | $816.37M | $287.97M | $216.60M | $175.85M | $152.10M | $154.40M | $139.22M | $134.36M | $141.48M |
| Total equity incl. NCI | -$2.50B | -$2.27B | -$2.08B | -$1.92B | -$1.78B | -$1.64B | -$1.46B | -$1.22B | -$1.08B | -$1.04B |
| Temporary (mezzanine) equity | -$1.02M | -$951.00K | -$570.00K | $23.00K | -$445.00K | -$227.00K | $142.00K | $645.00K | -$223.00K | $525.00K |
| Inventory | $52.84M | $32.98M | $26.75M | $24.53M | $18.28M | $3.95M | $0 | Unavailable | Unavailable | Unavailable |
| Accounts receivable | $254.48M | $205.23M | $139.44M | $116.52M | $76.87M | $115.26M | $4.72M | Unavailable | Unavailable | Unavailable |
| Goodwill | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Long-term debt | $2.65B | $2.65B | $2.01B | $2.01B | $0 | $0 | $437.34M | $436.22M | $435.45M | $434.72M |
| Accounts payable | $27.20M | $29.06M | $36.23M | $18.70M | $26.13M | $27.52M | $9.62M | $13.36M | $18.13M | $4.73M |
Cash flow
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$71.10M | -$197.28M | -$56.42M | -$109.57M | -$80.68M | -$199.24M | -$195.33M | -$180.57M | $74.70M | -$219.54M |
| Capital expenditures | $443.00K | $69.00K | $33.00K | $470.00K | $594.00K | $0 | $47.00K | $137.00K | $54.00K | $695.00K |
| Investing cash flow | $17.89M | -$42.74M | -$14.35M | $4.46M | -$13.00M | -$1.60M | -$3.24M | $38.23M | $3.04M | $22.75M |
| Financing cash flow | -$148.77M | $549.89M | -$2.18M | -$894.00K | $302.04M | $60.33M | $473.93M | $707.00K | -$5.73M | $279.55M |
| Net change in cash | -$201.98M | $309.88M | -$72.96M | -$106.00M | $208.36M | -$140.50M | $275.37M | -$141.63M | $72.01M | $82.76M |
| Stock-based compensation | $44.07M | $33.24M | $34.64M | $35.26M | $37.24M | $25.88M | $30.13M | $27.16M | $21.45M | $17.06M |
| Common dividends paid | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Common share repurchases | $127.50M | $82.50M | $0 | $0 | $0 | $48.28M | $0 | $0 | $0 | $0 |
| Depreciation & amortization | $1.05M | $1.19M | $1.44M | $1.40M | $1.32M | $1.28M | $1.37M | $1.54M | $1.57M | $1.60M |
Derived
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | -$71.54M | -$197.35M | -$56.45M | -$110.04M | -$81.28M | -$199.24M | -$195.37M | -$180.70M | $74.65M | -$220.23M |
| Gross margin | 93.8% | 94.9% | 94.7% | 94.6% | 96.7% | 97.7% | 64.6% | 78.1% | 72.4% | 99.7% |
| Operating margin | -43.9% | -54.5% | -90.5% | -120.3% | -121.4% | -89.5% | -3842.7% | -7018.7% | -8096.8% | 0.2% |
| FCF margin | -29.4% | -101.5% | -36.6% | -91.2% | -73.5% | -170.8% | -3321.5% | -6614.3% | 3443.2% | -104.3% |
| SBC / revenue | 18.1% | 17.1% | 22.5% | 29.2% | 33.7% | 22.2% | 512.2% | 994.2% | 989.6% | 8.1% |
| Current ratio | 1.23x | 1.52x | 2.77x | 3.88x | 5.19x | 4.57x | 4.67x | 3.19x | 4.59x | 5.54x |
| Revenue YoY growth | 120.4% | 66.8% | 2521.2% | 4318.0% | 4999.9% | -44.8% | 237.1% | -33.2% | 32.1% | 11461.9% |
| Net margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| R&D / revenue | 61.3% | 65.1% | 75.5% | 93.5% | 100.6% | 95.5% | 2216.1% | 4408.6% | 5290.4% | 66.8% |
| CapEx / revenue | 0.2% | 0.0% | 0.0% | 0.4% | 0.5% | 0.0% | 0.8% | 5.0% | 2.5% | 0.3% |
| Long-term debt / equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BBIO in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-24View SEC filing
10-Q · Filed 2025-10-29View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-04-29View SEC filing
Reconciliation checks needing review
2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.
balance equationreview2022-09-30
Difference 2388000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.